H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy By Investing.com
H.C. Wainwright has reiterated its Buy rating on Palvella Therapeutics (NASDAQ:PVLA) with a $270.00 price target, despite a recent 21% stock decline following an updated corporate presentation. The FDA recently declined Breakthrough Therapy Designation for cVM, but the firm believes this denial has limited …